Recent studies have shown that significantly lower CD59 correlates with poor survival in breast cancer, while high expression of CD59 protein induced decreased overall survival rates in colorectal cancer, prostate cancer, etc. [59,60,61]. This evidence concerns the gene CD59 and prostate carcinoma.